|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KCNJ5 |
Gene summary for KCNJ5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KCNJ5 | Gene ID | 3762 |
| Gene name | potassium inwardly rectifying channel subfamily J member 5 | |
| Gene Alias | CIR | |
| Cytomap | 11q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | P48544 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3762 | KCNJ5 | HCC1 | Human | Liver | HCC | 5.48e-23 | 2.99e+00 | 0.5336 |
| 3762 | KCNJ5 | HCC2 | Human | Liver | HCC | 1.97e-32 | 2.23e+00 | 0.5341 |
| 3762 | KCNJ5 | HCC5 | Human | Liver | HCC | 1.25e-40 | 2.13e+00 | 0.4932 |
| 3762 | KCNJ5 | S029 | Human | Liver | HCC | 2.88e-04 | 2.58e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KCNJ5 | SNV | Missense_Mutation | rs372447456 | c.133N>A | p.Glu45Lys | p.E45K | P48544 | protein_coding | tolerated(0.49) | benign(0.107) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| KCNJ5 | SNV | Missense_Mutation | novel | c.344N>T | p.Arg115Leu | p.R115L | P48544 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| KCNJ5 | SNV | Missense_Mutation | novel | c.797N>C | p.Asp266Ala | p.D266A | P48544 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| KCNJ5 | SNV | Missense_Mutation | rs529755922 | c.10G>A | p.Asp4Asn | p.D4N | P48544 | protein_coding | deleterious_low_confidence(0.02) | benign(0.027) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| KCNJ5 | SNV | Missense_Mutation | novel | c.1027N>C | p.Phe343Leu | p.F343L | P48544 | protein_coding | tolerated(0.63) | probably_damaging(0.996) | TCGA-PL-A8LX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| KCNJ5 | SNV | Missense_Mutation | novel | c.1198N>G | p.Gln400Glu | p.Q400E | P48544 | protein_coding | tolerated(1) | benign(0) | TCGA-C5-A8YT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| KCNJ5 | SNV | Missense_Mutation | c.110C>T | p.Thr37Ile | p.T37I | P48544 | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KCNJ5 | SNV | Missense_Mutation | c.154C>T | p.Arg52Cys | p.R52C | P48544 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-A6-6782-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| KCNJ5 | SNV | Missense_Mutation | rs781022847 | c.259C>T | p.Arg87Cys | p.R87C | P48544 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KCNJ5 | SNV | Missense_Mutation | novel | c.397C>A | p.Leu133Ile | p.L133I | P48544 | protein_coding | tolerated(0.25) | possibly_damaging(0.79) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3762 | KCNJ5 | TRANSPORTER, ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | FLUPIRTINE | FLUPIRTINE | ||
| 3762 | KCNJ5 | TRANSPORTER, ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | activator | 135652743 | ||
| 3762 | KCNJ5 | TRANSPORTER, ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | blocker | 135650721 | ||
| 3762 | KCNJ5 | TRANSPORTER, ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | phorbol 12-myristate 13-acetate | |||
| 3762 | KCNJ5 | TRANSPORTER, ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | blocker | 223366037 | ||
| 3762 | KCNJ5 | TRANSPORTER, ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | activator | 135651544 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |